Fundus Photography — CPB 0539 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0539 governing fundus photography coverage, effective September 26, 2025. Here's what billing teams need to do.

This update to the Aetna fundus photography coverage policy affects CPT 92250 — the primary billable code for fundus photography with interpretation and report, including Optomap imaging. CPB 0539 Aetna now draws sharper lines around frequency limits, medical necessity for normal retinas, and baseline imaging before MEK inhibitor therapy. If your practice bills ophthalmology, oncology, rheumatology, or infectious disease for Aetna members, this policy touches your claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Fundus Photography — CPB 0539
Policy Code	CPB 0539
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	Medium
Specialties Affected	Ophthalmology, Optometry, Oncology, Rheumatology, Infectious Disease, Neurology
Key Action	Confirm every CPT 92250 claim carries a covered ICD-10 diagnosis and does not exceed two studies per year without documented justification

---

Aetna Fundus Photography Coverage Criteria and Medical Necessity Requirements 2025

The Aetna fundus photography coverage policy is diagnosis-driven. CPT 92250 — fundus photography with interpretation and report — is covered only when the patient has a documented condition from Aetna's approved indication list.

The list is long. Over 40 conditions qualify, including diabetic retinopathy, age-related macular degeneration, glaucoma and glaucoma suspects, hypertensive retinopathy, sickle-cell anemia, HIV disease, toxoplasmosis, and multiple sclerosis. Drug-monitoring indications also qualify — specifically, patients on hydroxychloroquine (Plaquenil), chloroquine (Aralen), or other anti-malarials, as well as patients taking ethambutol (Myambutol) or pentosan polysulfate sodium (Elmiron).

Medical necessity depends on the diagnosis. A covered ICD-10 code must be present on the claim. Fundus photography of a normal retina is explicitly not medically necessary under this policy.

Frequency is the other trigger for claim denial. Aetna considers CPT 92250 medically necessary no more than twice per year. If your provider performs a third study in a calendar year, the medical record must document why — and that documentation needs to be in place before the claim goes out, not reconstructed after a denial.

This policy does not specifically mention prior authorization for CPT 92250. That said, prior auth requirements can vary by Aetna plan. Check the specific member's plan before assuming authorization isn't needed, especially for high-frequency cases or oncology patients receiving covered drugs like nivolumab (J9299) or durvalumab (J9173).

---

Aetna Fundus Photography Exclusions and Non-Covered Indications

Two specific situations are not covered under this policy, and both are worth calling out explicitly.

Normal retinas. Aetna will not reimburse CPT 92250 when there is no documented pathology. Routine wellness imaging of a normal retina — even if the provider considers it best practice — does not meet medical necessity under CPB 0539. Your ICD-10 must reflect an active condition from the covered list.

Baseline imaging before MEK inhibitor therapy. Aetna does not consider a baseline fundus photograph medically necessary before a patient starts a MEK inhibitor such as binimetinib (Mektovi), cobimetinib (Cotellic), or trametinib (Mekinist). This is a direct exclusion. If your oncology team routinely orders baseline fundus photography for patients starting these agents, those claims will not clear Aetna.

This MEK inhibitor exclusion is the sharpest edge of this policy update. Oncology billing teams need to know this now. The practice may be clinically standard at your institution, but Aetna will deny it. Document accordingly and align with your oncology medical director before September 26, 2025.

Computer-aided retinal analysis (0380T) is also not covered. CPT code 0380T — computer-aided animation and analysis of time series retinal images — does not meet Aetna's coverage criteria under CPB 0539. Do not bill this alongside CPT 92250 and expect reimbursement.

---

Coverage Indications at a Glance

---

Aetna Fundus Photography Billing Guidelines and Action Items 2025

These are the steps your billing and clinical teams should take before September 26, 2025.

Copy Action Items

If your practice spans multiple specialties — ophthalmology plus oncology plus rheumatology — the interaction between this policy and your drug-monitoring and oncology workflows is complex. Talk to your billing consultant or compliance officer before the September 26, 2025 effective date if you're not sure how your current charge capture handles all these scenarios.

---

CPT, HCPCS, and ICD-10 Codes for Fundus Photography Under CPB 0539

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
92250	CPT	Fundus photography with interpretation and report (includes Optomap)

Not Covered / Experimental Codes

Code	Type	Description	Reason Copy
0380T	CPT	Computer-aided animation and analysis of time series retinal images for the monitoring of disease progression	Does not meet Aetna coverage criteria under CPB 0539

HCPCS Codes — Drug Context for Covered Indications

These HCPCS codes appear in CPB 0539 in connection with indications where fundus photography monitoring is relevant (ethambutol, MEK inhibitors, and oncology drugs listed in the policy).

Key ICD-10-CM Diagnosis Codes

This policy includes 692 ICD-10-CM codes. The table below covers the most clinically relevant codes for fundus photography billing. Verify the full list at the Aetna CPB 0539 source policy.

The full ICD-10 list spans 692 codes across infectious disease, oncology, connective tissue disorders, congenital anomalies, and retinal pathology. Your billing team should map your most common diagnoses against the full Aetna list — not assume coverage because the category sounds right.

---